Stockscreener 앱 받기
5.8779
6.15%
0.3679
전일 마감가:
$5.51
열려 있는:
$5.59
하루 거래량:
207.05K
Relative Volume:
0.20
시가총액:
$321.85M
수익:
$1.02B
순이익/손실:
$-757.20M
주가수익비율:
-0.3982
EPS:
-14.76
순현금흐름:
$-257.90M
1주 성능:
+1.36%
1개월 성능:
-39.83%
6개월 성능:
-25.68%
1년 성능:
+148.88%
1일 변동 폭
$5.59
$6.01
1주일 범위
$5.26
$6.36
52주 변동 폭
$1.8201
$15.10
Emergent Biosolutions Inc Stock (EBS) Company Profile
명칭
Emergent Biosolutions Inc
전화
240-631-3200
주소
300 PROFESSIONAL DR, GAITHERSBURG, MD
EBS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
5.89 | 321.85M | 1.02B | -757.20M | -257.90M | -14.76 |
|
ZTS
Zoetis Inc
|
159.66 | 71.40B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.06 | 47.36B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.16 | 46.03B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.34 | 18.86B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.25 | 13.96B | 612.78M | -86.37M | -62.91M | -0.87 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-08-22 | 개시 | Rodman & Renshaw | Buy |
| 2024-03-07 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-11-20 | 재개 | JP Morgan | Underweight |
| 2023-08-29 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-04-10 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-03-17 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-11-10 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2022-04-29 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2022-01-20 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-11-08 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-05-05 | 다운그레이드 | Argus | Buy → Hold |
| 2021-04-07 | 개시 | The Benchmark Company | Buy |
| 2021-02-24 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2021-02-19 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2021-01-08 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-09-14 | 재개 | JP Morgan | Neutral |
| 2020-07-31 | 재확인 | Chardan Capital Markets | Buy |
| 2019-09-12 | 개시 | Guggenheim | Buy |
| 2019-09-04 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2018-11-02 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-08-03 | 재확인 | Chardan Capital Markets | Buy |
| 2018-06-13 | 개시 | Argus | Buy |
| 2018-04-25 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2018-01-24 | 개시 | Goldman | Neutral |
| 2018-01-16 | 재확인 | Chardan Capital Markets | Buy |
| 2016-06-28 | 재확인 | Singular Research | Buy |
| 2016-04-15 | 개시 | Chardan Capital Markets | Buy |
| 2016-03-28 | 개시 | Singular Research | Buy |
| 2016-02-19 | 개시 | Wells Fargo | Outperform |
| 2014-05-15 | 개시 | Summer Street Research | Buy |
| 2011-05-31 | 재확인 | WBB Securities | Strong Buy |
| 2011-01-10 | 재확인 | Wedbush | Outperform |
| 2010-11-05 | 재확인 | Wedbush | Outperform |
| 2010-08-18 | 업그레이드 | WBB Securities | Buy → Strong Buy |
| 2010-08-06 | 재확인 | Caris & Company | Buy |
모두보기
Emergent Biosolutions Inc 주식(EBS)의 최신 뉴스
Emergent BioSolutions to sell Baltimore-Bayview manufacturing site for $36.5M - MSN
Emergent signs financial investment agreement with Swiss Rockets - Yahoo Finance
Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs - The Manila Times
Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by ... - The Bakersfield Californian
First OTC Narcan Program Targets High-Risk Construction Workers to Combat Overdose Crisis - StockTitan
Emergent BioSolutions to invest in Rocketvax for vaccine developments - MSN
Emergent BioSolutions director Fowler sells $204,050 in stock - Investing.com India
Emergent BioSolutions director Zoon sells $57,300 in stock - Investing.com
Emergent BioSolutions director Fowler sells $204,050 in stock By Investing.com - Investing.com UK
Emergent Bio and Rocketvax in investment deal and partnership - The Pharma Letter
Emergent BioSolutions and Rocketvax Announce Investment Agreement - Contract Pharma
Emergent Biosolutions And Rocketvax Announce Investment Agreement And Pursuit Of A Strategic Relationship For Next-Generation Product Candidates - Marketscreener.com
Emergent BioSolutions to Invest in Swiss Rockets, Rocketvax -March 12, 2025 at 08:40 am EDT - Marketscreener.com
Emergent BioSolutions, Rocketvax announce investment agreement - TipRanks
Emergent BioSolutions and Rocketvax Ltd Announce Strategic Investment and Partnership to Advance Next-Generation Vaccine Development - Nasdaq
Emergent BioSolutions and Rocketvax Announce Investment - GlobeNewswire
Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates - GlobeNewswire Inc.
Rhumbline Advisers Trims Stock Position in Emergent BioSolutions Inc. (NYSE:EBS) - Defense World
Syngene buys its first manufacturing facility in US for USD36.5 million - Medical Dialogues
Emergent BioSolutions Sells Baltimore Facility to Syngene - TipRanks
Gaithersburg's Emergent BioSolutions to sell Baltimore plant for $36.5M - The Business Journals
Drug manufacturer to sell Baltimore plant for $36.5M - The Business Journals
Emergent BioSolutions sells Baltimore facility to Syngene By Investing.com - Investing.com Canada
Emergent BioSolutions drops after Syngene buys co's unit for $36.5 mln - TradingView
India's Syngene International acquires first US biologics facility for $36.5 million - Yahoo Finance
Emergent to Sell Baltimore-Bayview Facility for $36.5 Million -March 10, 2025 at 10:28 am EDT - Marketscreener.com
Emergent BioSolutions sells Baltimore facility to Syngene - Investing.com
Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International - The Manila Times
Emergent BioSolutions to sell Baltimore-Bayview facility for $36.5M - TipRanks
Emergent BioSolutions’ (EBS) Buy Rating Reiterated at HC Wainwright - Defense World
Q1 Earnings Estimate for EBS Issued By HC Wainwright - Defense World
Emergent BioSolutions Inc. (NYSE:EBS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - Yahoo Finance
Is Emergent BioSolutions (NYSE:EBS) Weighed On By Its Debt Load? - Simply Wall St
Emergent BioSolutions’ Earnings Call: Balancing Achievements and Challenges - TipRanks
Emergent BioSolutions Reports Strong 2024 Financial Turnaround - MSN
Where Emergent BioSolutions Stands With Analysts - Benzinga
Emergent BioSolutions Inc. (NYSE:EBS) Q4 2024 Earnings Call Transcript - Insider Monkey
H.C. Wainwright maintains Buy rating on Emergent BioSolutions stock By Investing.com - Investing.com UK
Emergent Bio's Q4 Revenue Plunges Nearly 30%, Forecasts 18% To 28% Drop For 2025 - Nasdaq
Emergent BioSolutions Inc. SEC 10-K Report - TradingView
(EBS) Trading Signals - Stock Traders Daily
Emergent BioSolutions Inc (EBS) Q4 2024 Earnings Call Highlights: Strategic Advancements Amid ... By GuruFocus - Investing.com Canada
Emergent BioSolutions Stock Sinks As Q4 Revenue Plunges 30%, But Retail Clings To Profit Swing - MSN
Emergent Biosolutions: Q4 Earnings Snapshot - Midland Daily News
Emergent BioSolutions (EBS) Q4 2024 Earnings Call Transcript - AOL
Emergent BioSolutions Inc Q4 2024 Earnings: EPS of -$0.58 Misses Estimate, Revenue Falls Short at $194.7 Million - GuruFocus.com
Emergent BioSolutions Inc (EBS) Q4 2024 Earnings Call Highlights: Strategic Advancements Amid ... - Yahoo Finance
Emergent BioSolutions Inc reports results for the quarter ended December 31Earnings Summary - TradingView
EMERGENT BIOSOLUTIONS Earnings Results: $EBS Reports Quarterly Earnings - Nasdaq
Emergent BioSolutions Swings to Q4 Earnings, Revenue Declines -- Shares Fall After Hours - Marketscreener.com
Emergent BioSolutions tumbles 8% as Q4 revenue, 2025 guidance disappoints - Seeking Alpha
Emergent Biosolutions Inc (EBS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.16%
0.86%
자본화:
|
볼륨(24시간):